2022
DOI: 10.1159/000526814
|View full text |Cite
|
Sign up to set email alerts
|

Recurrent Vestibulopathy: Comparison of Vestibular Test Results with Ménière’s Disease and Vestibular Migraine

Abstract: <b><i>Introduction:</i></b> Recurrent and episodic vestibular symptoms not fulfilling criteria for known episodic vestibular syndromes are named as recurrent vestibulopathy (RV). We aimed to compare the vestibular test results of RV patients with vestibular migraine (VM) and Ménière’s disease (MD). <b><i>Methods:</i></b> Twenty patients with MD, 20 patients with VM, 18 patients with RV, and 20 healthy volunteers (HC) were evaluated. Pure-tone hearing thresholds (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 52 publications
0
1
0
Order By: Relevance
“…A previous study reported that low cVEMP amplitudes on the affected side were the main feature in MD, differentiating it from VM. [52] Flook et al [53] found that a cytokine panel including interleukin 1, beta, Chemokine (C-C motif) ligand 3, Chemokine (C-C motif) ligand 22, and Chemokine (C-X-C motif) ligand 1, could be used as biological markers for the differential diagnosis of VM and MD, suggesting a high diagnostic value in patients with symptom overlap. Moreover, the team attempted to use prestin and otolin-1 as biomarkers to differentiate between MD and VM.…”
Section: Discussionmentioning
confidence: 99%
“…A previous study reported that low cVEMP amplitudes on the affected side were the main feature in MD, differentiating it from VM. [52] Flook et al [53] found that a cytokine panel including interleukin 1, beta, Chemokine (C-C motif) ligand 3, Chemokine (C-C motif) ligand 22, and Chemokine (C-X-C motif) ligand 1, could be used as biological markers for the differential diagnosis of VM and MD, suggesting a high diagnostic value in patients with symptom overlap. Moreover, the team attempted to use prestin and otolin-1 as biomarkers to differentiate between MD and VM.…”
Section: Discussionmentioning
confidence: 99%